Home News MANDARA: Benralizumab Proves Noninferiority to Mepolizumab for EGPA back to News
minute read
The publication of full trial results from the MANDARA trial further underlines the potential of benralizumab (Fasenra) in the ability to help adult patients achieve remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis.
Topics: Press Coverage
12631 East 17th Avenue
8601
Aurora, CO 80045
303-724-1785
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
